ObsEva (OBSV) PT Raised to $24 at BMO Capital

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/15/2026

1. NVDA
2. CRWV
3. SPY
4. BAC
5. BLK
6. AA
7. RKLB
8. CAT
9. FMC
10. MRSH

Go back to ObsEva (OBSV) PT Raised to $24 at BMO Capital

ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF

February 26, 2018 7:01 AM EST

The WHO considers infertility a global public health issue affecting 186 million people, and only 1 in 4 ART treatments results in childbirth

Geneva, Switzerland and Boston, MA - 26 February, 2018 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today reported positive top line results of the IMPLANT2 Phase 3 clinical trial of its oral oxytocin receptor antagonist, nolasiban, which is being developed for improving pregnancy rate following in vitro fertilization/intracytoplasmic sperm injection... More